

Evaluation of the new kit STA-vWf RCO (STAGO) measuring Willebrand factor activity and comparison with two SIEMENS kits: BC von Willebrand Reagent and Innovance vW activity



Cédrick Goudji, Isabelle Courtois, Julie Yernaux, Marine Blauwaert, Danielle Govaerts, Philippe Cauchie.

Laboratory of clinical biology CHU de Charleroi, Belgique.

Introduction

Ristocetin cofactor assay has become one of the key elements in the diagnosis of von Willebrand disease (vWD), the most common hereditary hemostasis disorder. Its measurement is associated with that of vWf (von Willebrand factor) antigen for the diagnosis of type II vWD, in the measurement of the "vWf RCO / vWf-Ag" ratio.

Aim


Evaluation of the new STAGO "STA-vWf RCO" kit for ristocetin cofactor assay, and comparison with two kits for vWf assay in the diagnosis of von Willebrand disease.

Materials and Methods

Two ristocetin cofactor assays: STA-VWF: RCO (Diagnostica Stago) on STA-R® MAX2; BC VWF Reagent (Siemens Healthcare Diagnostics) and a VWF:GP1BM assay: Innovance AC (Siemens Healthcare Diagnostics) on BCS-XP®. All tests were performed following manufacturer's intructions.

Patients: n = 81; Type I = 8; Type II = 11; AVWS = 3; Normal = 59

Results



Conclusion

This new STA-VWF: RCO kit shows satisfactory results with a repeatability of less than 10% and a reproducibility of less than 17%. We suggest the use of the kit for medium-sized series or as a second-line test in reference laboratories.